{ "name": "The HRT Index U.S. Menopause HRT Supply Monitor", "snapshot_id": "HRTI-HRTS-US-2026-10-03-v1", "tracker_verified_at": "2026-10-03", "country": "United States", "scope": "Prescription estrogen and progestogen products commonly used for menopause and perimenopause", "headline_findings": { "ashp_current_product_groups": 4, "matching_fda_current_product_groups": 0, "affected_presentation_entries": 28, "source_listed_available_entries": 38 }, "source_agreement_taxonomy": [ "Both", "ASHP-only", "FDA-only", "Neither/local report only" ], "methodology": { "fda_query_terms": [ "estradiol", "estrogen", "progesterone", "medroxyprogesterone", "norethindrone", "conjugated", "bazedoxifene" ], "presentation_counting_rule": "Count each ASHP affected-products or available-products line item as one presentation entry.", "source_age_rule": "Tracker verification date minus the primary source date.", "current_status_rule": "Preserve FDA and ASHP status separately; do not infer local inventory or therapeutic interchangeability.", "fda_query": "generic_name:(estradiol OR estrogen OR progesterone OR medroxyprogesterone OR norethindrone OR conjugated OR bazedoxifene)", "scope_note": "The original tracker explicitly checked estradiol injections. The new current ASHP estradiol valerate injection bulletin is now included; its inclusion does not imply that injections are a common first-line menopause choice." }, "fda_extraction_receipt": { "retrieved": "2026-10-03", "method": "Targeted openFDA drug-shortage API query; not a full FDA export", "database_last_updated": "2026-10-02", "source_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%28estradiol+OR+estrogen+OR+progesterone+OR+medroxyprogesterone+OR+norethindrone+OR+conjugated+OR+bazedoxifene%29&skip=0&limit=10", "rows_parsed": 3, "total_matching": 3, "pagination_truncated": false, "maximum_matching_record_update_date": "2026-08-31", "matching_record_status_counts": { "Current": 0, "To Be Discontinued": 3, "Resolved": 0 }, "matching_hormone_term_rows": [ { "generic_name": "Medroxyprogesterone Acetate Tablet", "company_name": "Pfizer Inc.", "presentation": "PROVERA, Tablet, 10 mg (NDC 0009-0051-01)", "status": "To Be Discontinued", "date_of_update": "2026-08-31", "included_in_current_shortage_count": false, "source_url": "https://api.fda.gov/drug/shortages.json?search=package_ndc%3A%220009-0051-01%22&skip=0&limit=1" }, { "generic_name": "Progesterone Vaginal Gel", "company_name": "AbbVie Inc.", "presentation": "Crinone, Vaginal Gel, 4% (NDC 0023-6150-04)", "status": "To Be Discontinued", "date_of_update": "2026-03-27", "included_in_current_shortage_count": false, "source_url": "https://api.fda.gov/drug/shortages.json?search=package_ndc%3A%220023-6150-04%22&skip=0&limit=1" }, { "generic_name": "Medroxyprogesterone Acetate Tablet", "company_name": "Pfizer Inc.", "presentation": "PROVERA, Tablet, 2.5 mg (NDC 0009-0065-01)", "status": "To Be Discontinued", "date_of_update": "2026-08-31", "included_in_current_shortage_count": false, "source_url": "https://api.fda.gov/drug/shortages.json?search=package_ndc%3A%220009-0065-01%22&skip=0&limit=1" } ], "provider_request_id": "5751caeb-9373-4327-abed-f974f257d842" }, "records": [ { "snapshot_id": "HRTI-HRTS-US-2026-10-03-v1", "tracker_verified_at": "2026-10-03", "country": "United States", "scope": "Prescription estrogen and progestogen products commonly used for menopause and perimenopause", "product_group": "Estradiol transdermal system", "route": "Transdermal", "ashp_status": "Current", "fda_current_match": "No", "source_agreement": "ASHP-only", "affected_presentation_count": 17, "source_listed_available_count": 29, "ashp_first_posted": "2026-01-30", "ashp_source_date": "2026-08-12", "source_age_days": 52, "resupply_estimate_state": "Mixed: affected once-weekly and twice-weekly presentations; allocation, intermittent supply, and back orders without release estimates", "ashp_source_url": "https://www.ashp.org/drug-shortages/current-shortages/drug-shortage-detail.aspx?id=1206", "fda_source_url": "https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm" }, { "snapshot_id": "HRTI-HRTS-US-2026-10-03-v1", "tracker_verified_at": "2026-10-03", "country": "United States", "scope": "Prescription estrogen and progestogen products commonly used for menopause and perimenopause", "product_group": "Progesterone capsules", "route": "Oral", "ashp_status": "Current", "fda_current_match": "No", "source_agreement": "ASHP-only", "affected_presentation_count": 4, "source_listed_available_count": 4, "ashp_first_posted": "2026-05-14", "ashp_source_date": "2026-08-17", "source_age_days": 47, "resupply_estimate_state": "Amneal 100 mg and 200 mg and Hikma 200 mg backordered without an estimate; Hikma 100 mg on allocation", "ashp_source_url": "https://www.ashp.org/drug-shortages/current-shortages/drug-shortage-detail.aspx?id=1227", "fda_source_url": "https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm" }, { "snapshot_id": "HRTI-HRTS-US-2026-10-03-v1", "tracker_verified_at": "2026-10-03", "country": "United States", "scope": "Prescription estrogen and progestogen products commonly used for menopause and perimenopause", "product_group": "Estradiol vaginal cream", "route": "Vaginal", "ashp_status": "Current", "fda_current_match": "No", "source_agreement": "ASHP-only", "affected_presentation_count": 3, "source_listed_available_count": 2, "ashp_first_posted": "2026-06-06", "ashp_source_date": "2026-06-06", "source_age_days": 119, "resupply_estimate_state": "Source still carries June and July estimates; elapsed estimates are unconfirmed, not evidence of fulfillment or continuing delay", "ashp_source_url": "https://www.ashp.org/drug-shortages/current-shortages/drug-shortage-detail.aspx?id=1229", "fda_source_url": "https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm" }, { "snapshot_id": "HRTI-HRTS-US-2026-10-03-v1", "tracker_verified_at": "2026-10-03", "country": "United States", "scope": "Prescription estrogen and progestogen products commonly used for menopause and perimenopause", "product_group": "Estradiol valerate injection", "route": "Intramuscular", "ashp_status": "Current", "fda_current_match": "No", "source_agreement": "ASHP-only", "affected_presentation_count": 4, "source_listed_available_count": 3, "ashp_first_posted": "2026-09-15", "ashp_source_date": "2026-09-15", "source_age_days": 18, "resupply_estimate_state": "Some 20 mg/mL presentations limited; Hikma 20 mg/mL estimated mid-to-late October 2026 and 40 mg/mL has no release estimate", "ashp_source_url": "https://www.ashp.org/drug-shortages/current-shortages/drug-shortage-detail.aspx?id=1246", "fda_source_url": "https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm" } ], "limitations": [ "National status does not show inventory at an individual pharmacy.", "Presentation-entry counts are not patient, prescription, package, inventory, or market-share counts.", "Source-listed availability does not establish therapeutic interchangeability.", "Elapsed manufacturer estimates remain unconfirmed until an authoritative source changes.", "Testosterone products are outside this dataset’s declared estrogen-and-progestogen scope." ], "uk_ssp_context": { "checked_at": "2026-10-03", "source_url": "https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/serious-shortage-protocols-ssps", "protocols": [ "SSP079", "SSP080", "SSP081", "SSP082" ], "latest_amendment": "2026-10-02", "end_date": "2027-01-08", "separate_unit_not_in_us_total": true } }